Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04205812 · ClinicalTrials.gov registry record · Phase 3
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
A Phase 3 study of Metastatic Squamous Non-Small Cell Lung Cancer and Metastatic Nonsquamous Non-Small Cell Lung Cancer, sponsored by Incyte Corporation.
- Active
- Registry status
- Phase 3
- Development phase
- 583
- Enrollment target
- 20
- Study locations
NCT04205812 is a Phase 3 study of Metastatic Squamous Non-Small Cell Lung Cancer and Metastatic Nonsquamous Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Incyte Corporation. The registered enrollment target is 583 participants. The trial reports 20 study locations across 3 states.
The verdict
NCT04205812, a Phase 3 study of Metastatic Squamous Non-Small Cell Lung Cancer and Metastatic Nonsquamous Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Incyte Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 583 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Placebo
- DRUG Retifanlimab
- DRUG Cisplatin
- DRUG Pemetrexed
Study Locations (20)
Other
- Fundacao Pio Xii Hospital de Cancer de Barretos - Barretos
- Incan - Instituto Do Cancer - Hospital Pompeia - Caxias do Sul
- Centro Regional Integrado de Oncologia - Fortaleza
- Oncosite - Centro de Pesquisa Clinica E Oncologia - Ijuí
- Clinica de Neoplasias Litoral Ltda - Itajaí
- Hospital Do Cancer de Londrina - Londrina
- Instituto Mederi de Pesquisa E Saude - Passo Fundo
- Hgb - Hospital Giovanni Battista - Mae de Deus Center - Porto Alegre
- Inca - Instituto Nacional de Cancer - Rio de Janeiro
- Sao Camilo Oncologia - S?O Paulo
- Cepho - Centro de Estudos E Pesquisas de Hematologia E Oncologia - Santo André
- Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto - São José
- Mc Women'S Health-Nadezhda Eood - Sofia
- Acibadem Cityclinica Mhat Tokuda - Sofia
- Umhat Sv. Ivan Rilski Ead - Sofia
- Mhat Serdika Eood - Sofia
- Multiprofile Hospital For Active Treatment Central Onco Hospital Ood - Sofia
California
- Pacific Cancer Medical Center - Anaheim
- Innovative Clinical Research Institute - Whittier
Pennsylvania
- Reading Hospital and Medical Center - Reading
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 583 participants |
| Start Date | 2020-09-11 |
| Est. Completion | 2026-08-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04205812
The ClinicalTrials.gov registry entry for NCT04205812 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 583 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Squamous Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT04205812 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04205812 about?
NCT04205812 is a clinical study titled "Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer". The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).
What is the current status of trial NCT04205812?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 583 participants. The study started on 2020-09-11. Estimated completion is 2026-08-28.
What conditions does trial NCT04205812 study?
This clinical trial studies the following conditions: Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT04205812?
The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Retifanlimab (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT04205812?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04205812 being conducted?
This trial has 20 study locations across California, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Metastatic Squamous Non-Small Cell Lung Cancer
All registered trials for this condition
Metastatic Nonsquamous Non-Small Cell Lung Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.